Thus, our results confirm that activation of the Akt/mTOR pathway contributes to tamoxifen resistance in breast cancer, but also reveal a novel mechanism for regulation of the Akt/mTOR signaling pathway involving the SALL2–PTEN axis. The gene discussed is PTEN; the disease is breast carcinoma.